Literature DB >> 16339521

Targeting LFA-1 and cd154 suppresses the in vivo activation and development of cytolytic (cd4-Independent) CD8+ T cells.

Keri E Lunsford1, Mitchel A Koester, Anna M Eiring, Phillip H Horne, Donghong Gao, Ginny L Bumgardner.   

Abstract

Short-term immunotherapy targeting both LFA-1 and CD40/CD154 costimulation produces synergistic effects such that long-term allograft survival is achieved in the majority of recipients. This immunotherapeutic strategy has been reported to induce the development of CD4+ regulatory T cells. In the current study, the mechanisms by which this immunotherapeutic strategy prevents CD8+ T cell-dependent hepatocyte rejection in CD4 knockout mice were examined. Combined blockade of LFA-1 and CD40/CD154 costimulation did not influence the overall number or composition of inflammatory cells infiltrating the liver where transplanted hepatocytes engraft. Expression of T cell activation markers CD43, CD69, and adhesion molecule CD103 by liver-infiltrating cells was suppressed in treated mice with long-term hepatocellular allograft survival compared to liver-infiltrating cells of untreated rejector mice. Short-term immunotherapy with anti-LFA-1 and anti-CD154 mAb also abrogated the in vivo development of alloreactive CD8+ cytotoxic T cell effectors. Treated mice with long-term hepatocyte allograft survival did not reject hepatocellular allografts despite adoptive transfer of naive CD8+ T cells. Unexpectedly, treated mice with long-term hepatocellular allograft survival demonstrated prominent donor-reactive delayed-type hypersensitivity responses, which were increased in comparison to untreated hepatocyte rejectors. Collectively, these findings support the conclusion that short-term immunotherapy with anti-LFA-1 and anti-CD154 mAbs induces long-term survival of hepatocellular allografts by interfering with CD8+ T cell activation and development of CTL effector function. In addition, these recipients with long-term hepatocellular allograft acceptance show evidence of immunoregulation which is not due to immune deletion or ignorance and is associated with early development of a novel CD8+CD25high cell population in the liver.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16339521     DOI: 10.4049/jimmunol.175.12.7855

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

Review 1.  Molecular mechanism and function of CD40/CD40L engagement in the immune system.

Authors:  Raul Elgueta; Micah J Benson; Victor C de Vries; Anna Wasiuk; Yanxia Guo; Randolph J Noelle
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

2.  Critical role of effector macrophages in mediating CD4-dependent alloimmune injury of transplanted liver parenchymal cells.

Authors:  Phillip H Horne; Jason M Zimmerer; Mason G Fisher; Keri E Lunsford; Gyongyi Nadasdy; Tibor Nadasdy; Nico van Rooijen; Ginny L Bumgardner
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

3.  A critical precursor frequency of donor-reactive CD4+ T cell help is required for CD8+ T cell-mediated CD28/CD154-independent rejection.

Authors:  Mandy L Ford; Maylene E Wagener; Samantha S Hanna; Thomas C Pearson; Allan D Kirk; Christian P Larsen
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

4.  Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway.

Authors:  Fabienne Haspot; Thomas Fehr; Carrie Gibbons; Guiling Zhao; Timothy Hogan; Tasuku Honjo; Gordon J Freeman; Megan Sykes
Journal:  Blood       Date:  2008-06-24       Impact factor: 22.113

5.  Endogenous memory CD8 T cells directly mediate cardiac allograft rejection.

Authors:  C A Su; S Iida; T Abe; R L Fairchild
Journal:  Am J Transplant       Date:  2014-02-06       Impact factor: 8.086

6.  Nanoparticles targeting dendritic cell surface molecules effectively block T cell conjugation and shift response.

Authors:  Chuda Chittasupho; Laura Shannon; Teruna J Siahaan; Charlotte M Vines; Cory Berkland
Journal:  ACS Nano       Date:  2011-03-04       Impact factor: 15.881

7.  Inhibition of recall responses through complementary therapies targeting CD8+ T-cell- and alloantibody-dependent allocytotoxicity in sensitized transplant recipients.

Authors:  Jason M Zimmerer; Phillip H Horne; Lori A Fiessinger; Mason G Fisher; Kartika Jayashankar; Sierra F Garcia; Mahmoud Abdel-Rasoul; Nico van Rooijen; Ginny L Bumgardner
Journal:  Cell Transplant       Date:  2012-10-11       Impact factor: 4.064

8.  Beta2 integrins separate graft-versus-host disease and graft-versus-leukemia effects.

Authors:  Yaming Liang; Chen Liu; Julie Y Djeu; Bin Zhong; Thorsten Peters; Karin Scharffetter-Kochanek; Claudio Anasetti; Xue-Zhong Yu
Journal:  Blood       Date:  2007-10-10       Impact factor: 22.113

9.  Regulatory roles of CD1d-restricted NKT cells in the induction of toxic shock-like syndrome in an animal model of fatal ehrlichiosis.

Authors:  H L Stevenson; E C Crossley; N Thirumalapura; D H Walker; N Ismail
Journal:  Infect Immun       Date:  2008-01-22       Impact factor: 3.441

10.  Alloreactive (CD4-Independent) CD8+ T cells jeopardize long-term survival of intrahepatic islet allografts.

Authors:  K E Lunsford; K Jayanshankar; A M Eiring; P H Horne; M A Koester; D Gao; G L Bumgardner
Journal:  Am J Transplant       Date:  2008-06       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.